FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | Contact Us | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages

Start Over | Back to Previous Screen

Erythromycin Ophthalmic Ointment
Status: Currently in Shortage
»Date first posted: 07/06/2022
»Therapeutic Categories: Ophthalmology; Pediatric

Expand all

Akorn Pharmaceuticals (Revised 03/01/2023)

Company Contact Information:
800-932-5676

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Erythromycin Ophthalmic Ointment 0.5%: 3.5 g tube (NDC 17478-070-35)	Not available	No new manufacturing of product
Erythromycin Ophthalmic Ointment 0.5%: 1 g tube (unit dose) (NDC17478-070-31)	Not available	No new manufacturing of product

Bausch Health (Revised 08/01/2022)

Company Contact Information:
800-321-4576

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Erythromycin Ophthalmic Ointment USP, 0.5% 3.5 g in 1 tube (NDC 24208-910-55)	Limited availability. Manufacturing and distribution is ongoing. Increase in demand orders will be taken on a case-by-case basis.	CDC	Demand increase for the drug
Erythromycin Ophthalmic Ointment USP, 0.5% 1 g in carton of 50 (NDC 24208-910-19)	Limited availability. Manufacturing and distribution is ongoing. Increase in demand orders will be taken on a case-by-case basis.	CDC	Demand increase for the drug

Padagis US LLC (Revised 08/01/2022)

Company Contact Information:
763-732-0225

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Erythromycin 0.5% Ophthalmic Ointment 3.5 gram, 24-count (00574-4024-39)	Available and shipping	CDC	Demand increase for the drug
Erythromycin 0.5% Ophthalmic Ointment 1 gram, 50-count (00574-4024-50)	Available and shipping	CDC	Demand increase for the drug
Erythromycin 0.5% Ophthalmic Ointment 3.5 gram, 1-count (00574-4024-35)	Available and shipping	CDC	Demand increase for the drug